Health and Fitness Health and Fitness
Mon, June 27, 2011
Sat, June 25, 2011
Fri, June 24, 2011
Thu, June 23, 2011
Wed, June 22, 2011
Tue, June 21, 2011
Mon, June 20, 2011
Sun, June 19, 2011
Fri, June 17, 2011
Thu, June 16, 2011
Wed, June 15, 2011
Tue, June 14, 2011
[ Tue, Jun 14th 2011 ] - Market Wire
Bond Labs Reports May Results
Mon, June 13, 2011
Fri, June 10, 2011
Thu, June 9, 2011
Wed, June 8, 2011
Tue, June 7, 2011
Mon, June 6, 2011
Sat, June 4, 2011
Fri, June 3, 2011
Thu, June 2, 2011
Wed, June 1, 2011
Tue, May 31, 2011

Dendreon Announces Webcast Presentation at NASDAQ OMX 26th Investor Program


//health-fitness.news-articles.net/content/2011/ .. ntation-at-nasdaq-omx-26th-investor-program.html
Published in Health and Fitness on Thursday, June 16th 2011 at 3:20 GMT by Market Wire   Print publication without navigation


Dendreon Announces Webcast Presentation at NASDAQ OMX 26th Investor Program -- SEATTLE, June 16, 2011 /PRNewswire/ --

Dendreon Announces Webcast Presentation at NASDAQ OMX 26th Investor Program

[ ]

SEATTLE, June 16, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: [ DNDN ]) today announced that management will present at the NASDAQ OMX 26th Investor Program in London on June 21, 2011 at 9:30 a.m. GMT (4:30 a.m. ET).

The presentation will be webcast live and available for replay from Dendreon's website, [ www.dendreon.com ].  If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE®, was approved by the FDA in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit [ http:// ][ www.dendreon.com ]/.

SOURCE Dendreon Corporation

[ Back to top ]

RELATED LINKS
[ http://www.dendreon.com ]


Publication Contributing Sources